MCID: OCL009
MIFTS: 58

Ocular Cancer

Categories: Neuronal diseases, Cancer diseases, Eye diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 14
Eye Carcinoma 12 14 69
Eye Neoplasms 42 69
Eye Cancer 52 41
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 69
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Eye Neoplasm 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 35 190.8
MeSH 42 D005134
NCIt 47 C3030 C6079

Summaries for Ocular Cancer

MedlinePlus : 41 cancer of the eye is uncommon. it can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. if the cancer starts inside the eyeball it's called intraocular cancer. the most common intraocular cancers in adults are melanoma and lymphoma. the most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. cancer can also spread to the eye from other parts of the body. treatment for eye cancer varies by the type and by how advanced it is. it may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to ocular melanoma and skin lipoma, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Ranibizumab and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises_from the tissues that cover structures located in the eye.

Wikipedia : 72 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
id Related Disease Score Top Affiliating Genes
1 ocular melanoma 31.0 CCND1 CDKN1B CDKN2A RB1 TP53
2 skin lipoma 10.8 CDK4 MDM2 RB1
3 localized osteosarcoma 10.8 CDK4 MDM2 MYC
4 gangliosidosis gm1 10.8 MYC RB1
5 skeletal tuberculosis 10.8 CCND1 CDKN2A
6 rnase t2-deficient leukoencephalopathy 10.8 CDK4 MDM2 TP53
7 glioblastoma neural subtype 10.8 CDK4 CDK6
8 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
9 uremia 10.8 MYC POU5F1 SOX2
10 epidural neoplasm 10.8 CDK4 CDKN2A MDM2
11 breast epithelioid hemangioma 10.7 CDK4 MDM2 TP53
12 ascaridiasis 10.7 CDK4 MDM2 TP53
13 enamel hypoplasia cataract hydrocephaly 10.7 CDK4 MDM2 TP53
14 fallopian tube carcinosarcoma 10.7 BRCA2 MYC TP53
15 exertional headache 10.7 CDK4 CDKN2A RB1
16 adult liposarcoma 10.7 CDK4 CDKN2A MDM2
17 chest wall lymphoma 10.7 BRCA2 CCND1 TP53
18 acute cholinergic dysautonomia 10.7 CDKN1A MDM2 TP53
19 bone ameloblastoma 10.7 CDKN2A RB1
20 gestational choriocarcinoma 10.7 CDK4 MDM2 TP53
21 rectum squamous cell carcinoma 10.7 CDKN2A MDM2 TP53
22 primary pulmonary lymphoma 10.7 CDK4 MDM2
23 lichen nitidus 10.7 CDKN1A MDM2 TP53
24 endocervicitis 10.7 BRCA2 TP53
25 mycetoma 10.7 BRCA2 CCND1 TP53
26 retinal detachment 10.7 BRCA2 CDKN2A TP53
27 vitamin d-dependent rickets, type i 10.7 CDK4 MDM2 TP53
28 villous adenocarcinoma 10.7 CDKN2A MYC TP53
29 spindle cell sarcoma 10.7 CDK4 MDM2 TP53
30 prostate transitional cell carcinoma 10.7 CCND1 RB1 TP53
31 toxic megacolon 10.7 CDKN1A MDM2 TP53
32 encephalocraniocutaneous lipomatosis 10.6
33 intraocular lymphoma 10.6
34 juxtacortical chondrosarcoma 10.6 CDK4 CDKN2A MDM2 RB1
35 pancreatic somatostatinoma 10.6 BRCA2 CDKN2A TP53
36 adenosarcoma 10.6 CDK4 MDM2 TP53
37 facial hemiatrophy 10.6 BRCA2 CDKN2A IL2
38 extraosseous osteosarcoma 10.6 CDK4 CDKN2A MDM2 MYC
39 mixed extragonadal germ cell cancer 10.6 CCND1 MDM2 TP53
40 urethra adenocarcinoma 10.6 CCND1 MYC TP53
41 rare endometriosis 10.6 CDKN2A SOX2 TP53
42 medullomyoblastoma 10.6 CCND1 MYC TP53
43 gastrointestinal neuroendocrine tumor 10.6 CCND1 CDKN2A TP53
44 solitary plasmacytoma of chest wall 10.6 CCND1 CDKN1A IL2
45 acute allergic sanguinous otitis media 10.6 CCND1 IL2 MYC
46 split hand split foot nystagmus 10.6 CDKN2A TP53
47 integumentary system cancer 10.6 CCND1 CDKN2A TP53
48 sarcomatoid squamous cell skin carcinoma 10.6 CCND1 CDK6 CDKN2A
49 thoracic outlet syndrome 10.6 MYC POU5F1 SOX2 TP53
50 angelman syndrome due to imprinting defect in 15q11-q13 10.6 CCND1 CDKN1A CDKN2A

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 MDM2 CDK2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 CDK2 MDM2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 MYC CCND1 CDK2 MDM2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 CDK2 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.2 MYC RBL1 RBL2 SOX2 CDK6 CDKN1B
28 Decreased viability GR00221-A-2 10.2 RBL1 CDK6
29 Decreased viability GR00221-A-3 10.2 CDKN2A MYC
30 Decreased viability GR00221-A-4 10.2 CDKN2A SOX2 CDK6
31 Decreased viability GR00301-A 10.2 CDK6
32 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 CDKN1A CDKN2A IL2 RB1 TP53 BRCA2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 CDKN1A CDKN2A IL2 RB1 TP53 BRCA2
34 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 BRCA2 CDK2 CDKN1A CDKN1B MDM2 TP53
35 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 CDK2 CDK4 CDK6 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

44 (show all 28)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 CDKN2A E2F4 IL2 MDM2 MYC POU5F1
2 endocrine/exocrine gland MP:0005379 10.58 CDKN1B CDKN2A E2F4 GNAQ IL2 MDM2
3 growth/size/body region MP:0005378 10.55 CDK6 CDKN1A CDKN1B CDKN2A BRCA2 E2F4
4 behavior/neurological MP:0005386 10.54 IL2 MDM2 MYC POU5F1 RB1 RBL1
5 cardiovascular system MP:0005385 10.53 CDKN2A E2F4 GNAQ IL2 MDM2 MYC
6 hematopoietic system MP:0005397 10.53 GNAQ IL2 MDM2 MYC POU5F1 RB1
7 homeostasis/metabolism MP:0005376 10.52 SOX2 TP53 ABCG2 BRCA2 CCND1 CDK2
8 immune system MP:0005387 10.51 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
9 integument MP:0010771 10.5 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
10 digestive/alimentary MP:0005381 10.49 BRCA2 CCND1 CDK4 CDKN1A CDKN1B CDKN2A
11 mortality/aging MP:0010768 10.49 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
12 embryo MP:0005380 10.48 RBL2 SOX2 TP53 CDK6 CDKN1A CDKN2A
13 neoplasm MP:0002006 10.41 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14 craniofacial MP:0005382 10.4 CCND1 CDKN1A CDKN1B E2F4 GNAQ MDM2
15 liver/biliary system MP:0005370 10.37 CDKN2A IL2 MDM2 MYC POU5F1 RB1
16 nervous system MP:0003631 10.36 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN1B
17 muscle MP:0005369 10.34 RBL1 RBL2 SOX2 TP53 CDK2 CDK4
18 hearing/vestibular/ear MP:0005377 10.28 CDKN1A CDKN1B E2F4 GNAQ MYC RB1
19 normal MP:0002873 10.25 RB1 RBL1 RBL2 SOX2 TP53 ABCG2
20 no phenotypic analysis MP:0003012 10.21 ABCG2 CDKN1A CDKN1B CDKN2A IL2 MDM2
21 reproductive system MP:0005389 10.21 SOX2 TP53 BRCA2 CCND1 CDK2 CDK4
22 limbs/digits/tail MP:0005371 10.19 BRCA2 CDKN1A GNAQ MDM2 MYC RB1
23 adipose tissue MP:0005375 10.18 ABCG2 CDKN1A CDKN1B MYC RB1 RBL1
24 pigmentation MP:0001186 10.02 CDK4 CDKN1B CDKN2A GNAQ MDM2 MYC
25 renal/urinary system MP:0005367 10.02 ABCG2 CDK4 CDKN1A CDKN1B GNAQ MDM2
26 respiratory system MP:0005388 9.93 CDKN2A E2F4 GNAQ IL2 RB1 RBL1
27 skeleton MP:0005390 9.8 BRCA2 CCND1 CDKN1A CDKN1B CDKN2A E2F4
28 vision/eye MP:0005391 9.4 SOX2 TP53 CCND1 CDK2 CDK4 CDKN1A

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1083)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 347396-82-1 459903
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
5
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
6
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
7
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
8
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
9
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
11
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 772 46507594
12
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
13
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
14
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
15
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
16
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
18
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
21
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
22
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
23
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
24
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
25
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
27
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
28
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
29
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
30
Codeine Approved, Illicit Phase 4 76-57-3 5284371
31
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 93-14-1 3516
32
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
33
Nicotine Approved Phase 4,Phase 2 54-11-5 942 89594
34
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
35
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
36
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
37
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
38
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
39
Trioxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 3902-71-4 5585
40
Bupivacaine Approved, Investigational Phase 4,Phase 3 2180-92-9, 38396-39-3 2474
41
Sufentanil Approved, Investigational Phase 4,Phase 3 56030-54-7 41693
42
Adalimumab Approved Phase 4,Phase 2,Phase 3,Phase 1 331731-18-1 16219006
43
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
44
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
45
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
46
Lamotrigine Approved, Investigational Phase 4,Phase 1,Phase 2 84057-84-1 3878
47
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
48
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
49
Topiramate Approved Phase 4,Phase 1,Phase 2 97240-79-4 5284627
50
Valproic Acid Approved, Investigational Phase 4,Phase 1,Phase 2 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 4330)

id Name Status NCT ID Phase Drugs
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
4 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
5 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
6 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
7 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
8 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
9 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
10 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
11 Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain Completed NCT00378937 Phase 4 acetaminophen;codeine phosphate;dextropropoxyphene hydrochloride;morphine sulfate;oxycodone hydrochloride
12 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
13 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
14 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
15 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
16 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Completed NCT01203917 Phase 4 Gefitinib
18 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
19 Intra-operative Digital vs. Standard Mammography Completed NCT01766102 Phase 4
20 Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
21 Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder Completed NCT01377168 Phase 4 oral naltrexone;Placebo pill
22 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
23 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
24 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 infliximab (remicade);Placebo
25 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
26 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
27 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial Completed NCT03024697 Phase 4
28 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4 brimonidine tartrate 0.2%
29 Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer Recruiting NCT02916745 Phase 4 Porfimer sodium
30 Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Recruiting NCT03016741 Phase 4 Prednisone;Abiraterone Acetate;Enzalutamide
31 Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery Recruiting NCT02314871 Phase 4 Piritramide;Morphine
32 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Recruiting NCT02895529 Phase 4 Itraconazole;Caspofungin
33 Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis Recruiting NCT01793519 Phase 4 Etanercept;Infliximab;Adalimumab;Placebo
34 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
35 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
36 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
37 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma Terminated NCT00216424 Phase 4 Capecitabine (Xeloda)
40 A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting Terminated NCT00418678 Phase 4 Cesamet
41 HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) Terminated NCT01849588 Phase 4 Sorafenib
42 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
43 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
44 PMCF-study Using Novosyn® Quick Suture Material in Ophthalmic Surgery Withdrawn NCT02761083 Phase 4
45 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
46 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
47 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
48 Tarceva Italian Lung Optimization tRial Unknown status NCT00637910 Phase 3 Erlotinib;Docetaxel
49 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
50 Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer Unknown status NCT00175383 Phase 3 luteinizing hormone-releasing hormone (LHRH) short acting or long acting

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

MalaCards organs/tissues related to Ocular Cancer:

39
Breast, Lung, Prostate, Eye, Brain, Bone, Liver

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show all 16)
id Title Authors Year
1
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. ( 28315914 )
2017
2
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. ( 27061559 )
2016
3
TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. ( 25834817 )
2015
4
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. ( 23441619 )
2013
5
The pathology of ocular cancer. ( 23154492 )
2013
6
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. ( 23181152 )
2010
7
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. ( 20127274 )
2010
8
Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. ( 19098995 )
2008
9
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. ( 17082795 )
2007
10
Non-cancerous ophthalmic clues to non-ocular cancer. ( 12431692 )
2002
11
Non-ocular cancer in relatives of retinoblastoma patients. ( 2789942 )
1989
12
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. ( 3356485 )
1988
13
Non-ocular cancer in retinoblastoma survivors. ( 2837050 )
1987
14
Photodynamic therapy of human ocular cancer. ( 2956549 )
1987
15
Non-ocular cancer in hereditary retinoblastoma survivors and relatives. ( 3587888 )
1987
16
Recent trends in the treatment of intra-ocular cancer. ( 13790869 )
1960

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 38)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13
2 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13
3 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13
4 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13
5 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13
6 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13
7 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13
8 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13
9 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13
10 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13
11 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13
12 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13
13 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13
14 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13
15 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13
16 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13
17 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13
18 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13
19 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13
20 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13
21 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13
22 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13
23 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13
24 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13
25 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13
26 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13
27 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13
28 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13
29 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13
30 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13
31 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13
32 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13
33 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13
34 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13
35 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13
36 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 13
37 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 13
38 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 13

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
2
Show member pathways
14.03 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
3
Show member pathways
13.9 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
4
Show member pathways
13.89 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
5
Show member pathways
13.62 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6
Show member pathways
13.3 CCND1 CDKN1B E2F4 GNAQ IL2 MYC
7
Show member pathways
13.17 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
8
Show member pathways
12.96 CCND1 CDK2 CDK4 CDK6 CDKN1B IL2
9 12.9 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
10 12.89 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
11
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
12
Show member pathways
12.87 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
13
Show member pathways
12.86 CCND1 CDKN1A CDKN1B IL2 MYC
14
Show member pathways
12.86 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
15
Show member pathways
12.77 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
16 12.76 CCND1 CDK6 CDKN1A CDKN1B CDKN2A MDM2
17
Show member pathways
12.73 CDK2 CDKN1A CDKN1B MDM2 TP53
18 12.73 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
19 12.69 CCND1 CDK4 CDKN1A CDKN2A IL2 MYC
20 12.69 CCND1 CDK2 CDK4 CDK6 E2F4 MYC
21 12.68 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
22
Show member pathways